The following table provides summary financial information comparing the third quarter 2024 ("Q3 2024”) financial results to the same quarter in 2023 ("Q3 2023”) as well as the nine-month ended ...
Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call an ...
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate sa ...
This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...
When it comes to the birth of a child, families want to know they are getting the highest quality care possible. Clinicians and staff of the Women and Children's department at Adena Regional Medical ...